Value through Innovation01 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
30.09.2014

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund

27.09.2014

Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only
27.09.2014

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

- For Ex-US and Ex-UK Media Only
26.09.2014

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

- For media outside UK and US only
18.09.2014

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For Ex-US and Ex-UK Media Only
16.09.2014

Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study

- For Non-U.S. and Non-UK Media
10.09.2014

European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe

- For Non-U.S. and Non-U.K. Media
09.09.2014

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting

- For Non-US and Non-UK Media
09.09.2014

Nintedanib* slowed disease progression in IPF independent of patients’ lung function impairment at baseline

- For media outside UK, US and Canada
08.09.2014

European Respiratory Society International Congress 2014
TONADO™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD

- For media outside the US, the UK and Canada
08.09.2014

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

 

- For Media outside the US, the UK & Canada only
02.09.2014

ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin

- Non-US/Non-UK/Non-Canadian Media
01.09.2014

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

- For Non-US/Non-UK/Non-Canadian Media
01.09.2014

Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward

01.09.2014

Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014

- For media outside UK, US and Canada
25.08.2014

New Pradaxa® data to be presented at the ESC Congress 2014

- For Non-US/Non-UK/Non-Canadian Media
22.08.2014

Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation

19.08.2014

First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting

- For Non-US/Non-UK/Non-Canadian Media
back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16